| Name | 2-{[4-(4-Hydroxy-1-piperidinyl)phenyl]amino}-11-methyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one |
|---|---|
| Synonyms |
2-{[4-(4-Hydroxy-1-piperidinyl)phenyl]amino}-11-methyl-5,11-dihydro-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one
6H-Pyrimido[4,5-b][1,4]benzodiazepin-6-one, 5,11-dihydro-2-[[4-(4-hydroxy-1-piperidinyl)phenyl]amino]-11-methyl- XMD16-5 |
| Description | XMD16-5 is a potent TNK2 inhibitor with IC50 values of 16 and 77 nM for the D163E and R806Q mutations, respectively. |
|---|---|
| Related Catalog | |
| Target |
IC50: 16 nM (TNK2, D163E mutation), 77 nM (TNK2, R806Q mutation)[1] |
| In Vitro | XMD16-5 potently inhibits the growth of the TNK2 mutant expressing cell lines while having little or no effect on the control cells out to the highest tested concentrations (1,000 nM). XMD16-5 has IC50s of 16 nM and 77 nM for the D163E and R806Q mutations. The effects of XMD16-5 on TNK2 cell lines are largely due to on-target effects on TNK2. Auto-phosphorylation of overexpressed TNK2 mutants could be blocked with TNK2 inhibitor XMD16-5[1]. |
| Kinase Assay | Kinase targets are tested with biochemical enzymatic kinase assays using the SelectScreen Kinase Profiling Service to determine IC50 values. The compounds (XMD16-5) are assayed at 10 concentrations (3-fold serial dilutions starting from 1 μM) at an ATP concentration equal to the ATP Km[1]. |
| Cell Assay | Cells are treated with the following inhibitors for 72 hours: dasatinib, AIM-100, XMD8-87 and XMD16-5. Cell viability is measured using a methanethiosulfonate (MTS)-based assay and absorbance (490 nm) is read at 1 and 3 hours after adding reagent[1]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C23H24N6O2 |
| Molecular Weight | 416.476 |
| Exact Mass | 416.196075 |
| LogP | 0.99 |
| Index of Refraction | 1.685 |
| Storage condition | -20℃ |
| Hazard Codes | N |
|---|